

Genetic dissection of the *miR-17~92* cluster of microRNAs in Myc-induced B-cell lymphomas

Ping Mu,^{1,5} Yoon-Chi Han,^{1,5} Doron Betel,² Evelyn Yao,¹ Massimo Squatrito,¹ Paul Ogradowski,¹ Elisa de Stanchina,³ Aleco D'Andrea,^{1,4} Chris Sander,² and Andrea Ventura^{1,6}

¹Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA; ²Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA; ³Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA; ⁴Department of Surgical and Oncological Sciences, Section of Medical Oncology, Università di Palermo, Palermo 90133, Italy

The *miR-17~92* cluster is frequently amplified or over-expressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA). *miR-17~92* is a direct transcriptional target of c-Myc, and experiments in a mouse model of B-cell lymphomas have shown cooperation between these two oncogenes. However, both the molecular mechanism underlying this cooperation and the individual miRNAs that are responsible for it are unknown. By using a conditional knockout allele of *miR-17~92*, we show here that sustained expression of endogenous *miR-17~92* is required to suppress apoptosis in Myc-driven B-cell lymphomas. Furthermore, we show that among the six miRNAs that are encoded by *miR-17~92*, *miR-19a* and *miR-19b* are absolutely required and largely sufficient to recapitulate the oncogenic properties of the entire cluster. Finally, by combining computational target prediction, gene expression profiling, and an in vitro screening strategy, we identify a subset of *miR-19* targets that mediate its pro-survival activity.

Supplemental material is available at <http://www.genesdev.org>.

Received October 11, 2009; revised version accepted November 3, 2009.

The *miR-17~92* cluster encodes six distinct microRNAs (miRNAs) that are processed from a common primary transcript (Fig. 1A; for review, see Mendell 2008). A growing body of evidence points to an important role of this cluster of miRNAs in the pathogenesis of human cancers (for review, see Ventura and Jacks 2009). Over-

expression of *miR-17~92* is observed in a large fraction of human cancers, including carcinomas of the breast, lung, and colon; medulloblastomas; neuroblastomas; and B-cell lymphomas (Hayashita et al. 2005; He et al. 2005; Tagawa and Seto 2005; Fontana et al. 2008; Uziel et al. 2009). In addition, a substantial fraction of diffuse large B-cell lymphomas harbors recurrent genomic amplification of the *miR-17~92* locus (Ota et al. 2004).

The evidence for a causal link between *miR-17~92* overexpression and tumorigenesis is strengthened by the observation that transgenic expression of this cluster in mice leads to a lymphoproliferative disorder (Xiao et al. 2008), while its genetic ablation impairs normal B-cell development (Ventura et al. 2008). In addition, ectopic expression of *miR-17~92* cooperates with the c-Myc oncogene in a mouse model of B-cell lymphomas (He et al. 2005). The functional interplay between *miR-17~92* and c-Myc is further underlined by the finding that c-Myc itself is a potent and direct transcriptional activator of *miR-17~92* (O'Donnell et al. 2005), thus suggesting that *miR-17~92* may contribute to the oncogenic properties of c-Myc.

The experiments presented in this study were designed to examine the role of the endogenous *miR-17~92* allele in Myc-driven lymphomas, and to determine the relative contribution of each of the six constituent miRNAs to the overall oncogenic potential of the cluster.

Our results show that, in the context of Myc-driven B-cell lymphomas, genetic ablation of the endogenous *miR-17~92* locus leads to a dramatic reduction of tumor cell growth in vitro and suppresses tumorigenicity in vivo, two effects that are largely the consequence of increased cell death. We also demonstrate that, among the six miRNAs encoded by the *miR-17~92* cluster, the members of the miR-19 family (*miR-19a* and *miR-19b*) are essential to mediate the oncogenic activity of the entire cluster, and that they do so at least in part by modulating the expression of the tumor suppressor gene *Pten* (phosphatase and tensin homologous).

Results and Discussion

Generation of *miR-17~92^{fllox/fllox};Eμ-Myc* mice

To investigate the role of *miR-17~92* in Myc-induced cancers, we employed the *Eμ-Myc* mouse model of B-cell lymphomas (Adams et al. 1985). *Eμ-Myc* mice express a c-Myc transgene under the control of the B-cell-specific *Eμ* enhancer and develop B-cell lymphomas within 4–6 mo of age (Adams et al. 1985). *Eμ-Myc* mice were crossed to mice carrying a conditional *miR-17~92* knockout allele (*miR-17~92^{fl}*) (Fig. 1B; Ventura et al. 2008). To temporally control the deletion of the floxed *miR-17~92* allele, these mice were further crossed to mice carrying a 4-hydroxytamoxifen (4-OHT)-inducible Cre-recombinase estrogen receptor-T2 (*Cre-ER^{T2}*) knock-in allele targeted to the ubiquitously expressed *ROSA26* locus (*R26-Cre-ER^{T2}* mice, hereafter referred to as *Cre-ER*) (Ventura et al. 2007).

As expected, *Eμ-Myc; miR-17~92^{fl/fl}; Cre-ER* mice developed B-cell lymphomas with similar latency and phenotype as the parental *Eμ-Myc* strain (data not shown). From these mice, we derived two independent lymphoma lines (AV4174 and AV4182) that could be

[Keywords: microRNAs; Myc; *miR-17~92*; cancer; mouse]

⁵These authors contributed equally to this work.

⁶Corresponding author.

E-MAIL ventura@mskcc.org; FAX (646) 422-0871.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1872909>.




Figure 1. *miR-17~92* suppresses cell death in *Eμ-Myc* lymphomas. (A) Schematic representation of the *miR-17~92* cluster. Each miRNA is represented by a colored box and is color-coded based on the seed family to which it belongs. The sequence of each mature miRNA is also shown. (B) Schematic of the conditional *miR-17~92* knockout allele. Arrows represent the primers used to detect the floxed and the deleted (Δ) alleles. (C) PCR on genomic DNA extracted from *Eμ-Myc;miR-17~92^{fl/fl};Cre-ER* lymphoma cells mock-treated or after 4 d of 4-OHT treatment. (D) Quantitative RT-PCR analysis of the expression of *miR-17~92* in lymphoma cells before (gray bars) and after (white bars) 4-OHT treatment. Each component of *miR-17~92* was detected independently, and the results were normalized relative to the expression observed in mock-treated cells. Each experiment was performed in quadruplicate. Error bar, standard deviation (SD). (E) Growth curves of *miR-17~92^{fl/fl}* cells (black line), *miR-17~92^{Δ/Δ}* cells (red line), and *miR-17~92^{Δ/Δ}* cells infected with a retrovirus expressing the entire *miR-17~92* cluster (blue line). Error bars, SD of three replicates. The plot is representative of three independent experiments. (F) Caspase activity in exponentially growing *miR-17~92^{fl/fl}* and *miR-17~92^{Δ/Δ}* lymphoma cells as detected by flow cytometry using FITC-conjugated VAD-FMK. The percent of VAD-FMK⁺ cells is shown.

propagated easily in culture and readily formed tumors when injected into immunocompromised mice. Both lymphoma lines exhibited similar behavior in vitro and in vivo. Unless otherwise specified, the experiments discussed here were performed using the AV4182 cell line.

To determine the efficiency of *miR-17~92* deletion, *miR-17~92^{fl/fl}* lymphoma cells were treated with 250 nM 4-OHT. This treatment led to the efficient deletion of both endogenous *miR-17~92* alleles (Fig. 1C), with concomitant loss of expression of the corresponding miRNAs (Fig. 1D).

We next examined the phenotypic consequences of deleting *miR-17~92* in B-lymphoma cells. Because sustained Cre expression has been reported to negatively affect the growth of *Eμ-Myc* lymphoma cells (Schmidt-Supprian and Rajewsky 2007), 4-OHT was administered for 4 d, after which the lymphoma cells were allowed to recover for a minimum of 4 d before being examined. As shown in Figure 1E, deletion of *miR-17~92* dramatically reduced the proliferation of *Eμ-Myc* lymphoma cells. Importantly, this phenotype was fully rescued by reintroduction of the entire *miR-17~92* cluster (Fig. 1E).

The different growth kinetics between the *miR-17~92^{fl/fl}* and *miR-17~92^{Δ/Δ}* lymphoma cells could be due to the latter displaying reduced proliferation, increased spontaneous cell death, or a combination of both.

While cell cycle distribution and BrdU incorporation were similar between *miR-17~92^{fl/fl}* and *miR-17~92^{Δ/Δ}* cells (Supplemental Fig. 1A), the fraction of cells undergoing apoptosis, as determined by detecting caspase activation, was approximately fourfold higher in the absence of *miR-17~92* (Fig. 1F). Increased apoptosis was confirmed by measuring the DNA fragmentation using the TUNEL assay (Supplemental Fig. 1B). These results demonstrate that expression of the endogenous *miR-17~92* locus is required for the optimal survival of Myc-driven B-lymphoma cells. In addition, they are consistent with the finding by He et al. (2005) that ectopic expression of *miR-17~92* cooperates with c-Myc by reducing spontaneous apoptosis.

miR-19a and miR-19b mediate the oncogenic properties of miR-17~92

This observation provides a rationale and an opportunity to genetically dissect the functions of this cluster and to identify its relevant target mRNAs. The six miRNAs encoded by *miR-17~92* can be grouped into four "seed families," based on sequence identity at positions 2–7 (Fig. 1A): the miR-17 family (*miR-17* and *miR-20a*), the miR-18 family (*miR-18a*), the miR-19 family (*miR-19a* and *miR-19b-1*), and the miR-92 family (*miR-92-1*). miRNAs belonging to the same seed family are predicted to target highly overlapping sets of mRNAs, and thus are expected to exert similar biological functions (Bartel 2009). To examine the role of each seed family in the context of *Eμ-Myc* lymphomas, we generated a series of *miR-17~92* mutant alleles, each lacking expression of the miRNA(s) belonging to one of the four seed families (Supplemental Fig. 2A). The wild-type and the mutant alleles of *miR-17~92* were cloned into MSCV-Puro-IRES-GFP (PIG), a retroviral vector encoding the green fluorescent protein (GFP) and the Puromycin resistance gene, and the resulting constructs were transduced into *miR-17~92^{Δ/Δ}* lymphoma cells. First, we verified that these constructs correctly expressed the desired miRNAs (Supplemental Fig. 2B). This was an essential control because deletion of even a single miRNA from the *miR-17~92* cluster could, in principle, negatively affect the processing and expression of the remaining ones, thus compromising our experimental approach.

To determine the ability of each construct to rescue the phenotype caused by *miR-17~92* deletion, we titrated the viral preparations to achieve an infection efficiency of 5%–30%, as judged by GFP expression. We reasoned that, if reintroduction of *miR-17~92* or one of its derivatives is sufficient to suppress the increased cell death observed in *miR-17~92^{Δ/Δ}* cells, it will provide the infected cells with a growth advantage that will in turn be reflected by an increase in the fraction of GFP-positive cells over time (see schematic in Fig. 2A). As predicted, reintroduction of the full-length *miR-17~92* cluster resulted in a rapid increase of GFP⁺ cells that quickly outcompeted the uninfected cells (Fig. 2B). Interestingly, among the four mutant constructs, only the one lacking the miR-19 seed family (Δ 19a, 19b) failed to provide a growth advantage (Fig. 2B,C) and to suppress the increased apoptosis caused by deletion of *miR-17~92* (Fig. 2D), suggesting that this seed family is necessary for the oncogenic properties of the cluster. This was further confirmed by showing that reintroduction of *miR-19a* and *miR-19b* alone was largely sufficient to rescue the growth defect caused by deletion




Figure 2. *miR-19a* and *miR-19b* mediate the prosurvival and oncogenic functions of *miR-17~92* in *Eμ-Myc* B-cell lymphomas. (A) Schematic of the experimental design. (B) Histogram overlays of *miR-17~92*^{Δ/Δ} cells transduced with PIG retroviruses expressing the indicated *miR-17~92* derivatives. The cells were assayed by flow cytometry to detect GFP expression at day 2 (blue plot) and day 8 (red plot) post-infection. A schematic of the *miR-17~92* derivative used is shown below each overlay. (C) Table summarizing the results of the experiments shown in B. (D) Caspase activity in *miR-17~92*^{fl/fl} and *miR-17~92*^{Δ/Δ} cells transduced with the indicated PIG constructs. Error bar, 1 SD deviation. (E) Survival analysis of mice injected with *miR-17~92*^{fl/fl} and *miR-17~92*^{Δ/Δ} lymphoma cells transduced with the indicated PIG constructs. *N* = 16 mice for each construct, over three independent experiments.

of the entire *miR-17~92* cluster and to suppress apoptosis (Fig. 2B,D, *miR-19a,b* construct).

Deletion of miR-19 affects tumorigenicity in vivo

To determine whether the miR-19 seed family is required for the tumorigenicity of *Eμ-Myc*-driven B-cell lymphomas *in vivo*, we injected a cohort of nude mice with *miR-17~92*^{fl/fl} and *miR-17~92*^{Δ/Δ} lymphoma cells. While *miR-17~92*^{fl/fl} cells invariably lead to the formation of lymphomas that lead to death within 2–3 wk, the *miR-17~92*^{Δ/Δ} cells produced lymphomas with a significantly (*P* < 0.0001) longer latency (Fig. 2E). Tumorigenicity was fully restored by ectopic expression of the full-length *miR-17~92* cluster (*P* < 0.0001), but not by expression of the *miR-17~92* mutant lacking *miR-19a* and *miR-19b* (*P* = 0.9816) (Fig. 2E). Re-expression of *miR-19a* and *miR-19b* also largely rescued tumorigenicity, although it did so somewhat less efficiently than the full-length *miR-17~92* (*P* = 0.0002 for the comparison between Δ/Δ and Δ/Δ + *miR-19a,b*; *P* = 0.0013 for the comparison between fl/fl and Δ/Δ + *miR-19a,b*).

Identification of miR-19 targets in B-cell lymphomas

Having demonstrated a critical role of *miR-19a* and *miR-19b* in *Myc*-driven B-cell lymphomas, we next sought to identify their functionally relevant target mRNAs. miRNA target prediction algorithms (TargetScan, Miranda, and Pictar) (John et al. 2004; Krek et al. 2005; Grimson et al. 2007; Betel et al. 2008) identify several hundreds of potential targets of miR-19; however, only a fraction of these mRNAs will likely be functionally relevant in any particular cellular context. To identify the genes whose expression is effectively modulated by *miR-*

17~92 in B-cell lymphomas, we compared the gene expression profile of the AV4182 cell line before and after deletion of *miR-17~92* (fl/fl vs. Δ/Δ). We also included *miR-17~92*^{Δ/Δ} lymphoma cells that had been transduced with either PIG-*miR-17~92*^{wt} or PIG-*miR-19a/19b* (Fig. 3A). In choosing this approach, we were supported by a number of recent reports showing that mRNA destabilization contributes to miRNA-mediated regulation of gene expression (Bagga et al. 2005; Lim et al. 2005; Baek et al. 2008; Selbach et al. 2008), which can be detected by conventional mRNA expression arrays. As predicted, deletion of *miR-17~92* led to the preferential up-regulation of genes whose 3' untranslated regions (UTRs) contain seed matches for the miRNAs encoded by this cluster (*P*-value < 2.22e-16, KS test) (Fig. 3B; Supplemental Fig. 3). Accordingly, ectopic expression of *miR-17~92* in *miR-17~92*^{Δ/Δ} cells led to the preferential down-regulation of *miR-17~92* targets (*P*-value < 2.22e-16, KS test) (Fig. 3C; Supplemental Fig. 3). Finally, reintroduction of a mutant version of the *miR-17~92* cluster expressing only *miR-19a* and *miR-19b* selectively affected mRNAs carrying binding sites for these two miRNAs (*P*-value = 6.35e-15), but not genes with binding sites for the other members of the *miR-17~92* cluster.

By comparing the four gene expression profiles, we identified a total of 568 genes whose expression was up-regulated (log₂ expression change >0.20) by deletion of the endogenous *miR-17~29* locus (fl/fl vs. Δ/Δ comparison) and down-regulated by the reintroduction of the full-length *miR-17~92* cluster (*miR-17~92* vs. Δ/Δ) and of *miR-19a* and *miR-19b* only (*miR-19a/b* vs. Δ/Δ; log₂ expression change <-0.20) (Fig. 3D). Ninety-five of them contained in their 3'UTR one or more conserved binding sites for miR-19, according to TargetScan 5.1 (Fig. 3E; Supplemental Table 1), and were analyzed further. Guided by our findings that miR-19 suppresses apoptosis in *Eμ-Myc* lymphoma cells, we inspected the list of 95 genes and selected a subset of 46 of them for functional validation (Fig. 4A; Supplemental Table 2). We reasoned that, if *miR-19* promotes survival by repressing the expression of one or more of these genes, this effect should be at least partially phenocopied by RNAi-mediated knockdown of the relevant targets. To test this hypothesis, for each of the 46 genes selected for validation we designed three shRNAs. The shRNAs were cloned into the MLP vector, a retroviral vector also expressing GFP, and each construct was individually transduced into *miR-17~92*^{Δ/Δ} lymphoma cells. Analogous to the experiments described in Figure 2A, the viral preparations were titrated in order to achieve a transduction efficiency of 5%–30%, and the fraction of GFP⁺ cells was measured 2 d after infection (day 0) and again 11 d later. The results of this experiment are summarized in Figure 4B. For the majority of shRNAs, the fraction of GFP⁺-positive cells did not change over time or, for a small number of them, was lower at day 11 compared with day 0, indicating that expression of the shRNA did not provide any growth advantage to the infected cells or was detrimental, respectively (Fig. 4B; Supplemental Table 2). However, for a subset of shRNAs, we observed a significant increase in




Figure 3. Gene expression profiling identifies *miR-19* targets in *Eμ-Myc* lymphoma cells. (A) Description of the various lymphoma cells used. (B) Differences in mRNA levels between *miR-17~92^{fl/fl}* and *miR-17~92^{Δ/Δ}* lymphoma cells transduced with the empty PIG vector were monitored with microarrays. Cumulative distribution function (CDF) plots are shown for mRNAs that do not contain *miR-17~92* seed matches in their 3'UTRs (black line), mRNAs containing one or more seed matches for *miR-19* in their 3'UTR (red line), and mRNAs containing one or more seed matches for either *miR-17*, *miR-20a*, *miR-18a*, or *miR-92* (blue line). In the absence of endogenous *miR-17~92* expression, a statistically significant up-regulation (P -value $< 2.22 \times 10^{-16}$, KS test) is observed for the predicted *miR-17~92* targets relative to the background gene population. (C) CDF plots of the changes in mRNA expression levels between *miR-17~92^{Δ/Δ}* + PIG-*miR-17~92* and *miR-17~92^{Δ/Δ}* lymphoma cells (left panel) and between *miR-17~92^{Δ/Δ}* + PIG-*miR-19a,b* and *miR-17~92^{Δ/Δ}* lymphoma cells (right panel). (D) Venn diagram summarizing the overlap in gene expression changes observed between the various transduction experiments. (E) As in D, but the analysis was restricted to mRNAs whose 3'UTR contains at least one predicted binding site for *miR-19*.

the fraction of GFP⁺ cells at day 11 compared with day 0 (Fig. 4B; Supplemental Fig. 5). Among them, two out of three shRNAs targeting the *Pten* tumor suppressor gene had the largest effect, largely phenocopying ectopic expression of *miR-19a/b*. A third shRNA directed against the *Pten* mRNA had a more modest, but still significant, effect. In addition, a number of the other shRNAs provided a significant growth advantage, although the effect was more modest than that observed with *Pten* shRNAs (Fig. 4B; Supplemental Table 2). In particular, all three shRNAs directed against *Sbf2* and two out of three directed against *Bcl7a* and *Rnf44* scored positive in this screening, suggesting that these three genes may contribute to the prosurvival functions of *miR-19*.

PTEN is one of the most frequently mutated tumor suppressor genes in human cancers, and monoallelic mutations at this locus are observed in $>50\%$ of sporadic tumors (for review, see Salmena et al. 2008). In mice, homozygous deletion of *Pten* leads to early embryonic lethality, while heterozygotes show greatly increased incidence of a variety of tumors, including T-cell lymphomas, as well as tumors of endometrium, liver, prostate, gastrointestinal tract, and thyroid (Di Cristofano

et al. 1998; Suzuki et al. 1998; Podsypanina et al. 1999). Functionally, *PTEN* is a phospholipid phosphatase that acts as a negative regulator of cell survival and protein synthesis via inhibition of the AKT/mammalian target of rapamycin (mTOR) pathway. Studies in mouse models and mutational analysis of human tumors indicate that *Pten* is an haploinsufficient tumor suppressor gene (Salmena et al. 2008), suggesting that even modest modulation of its levels by miRNAs may have functional consequences.

The *Pten* 3'UTR contains two conserved binding sites for *miR-19a* and *miR-19b* (Fig. 5A), and it has been shown previously to be a direct *miR-19* target (O'Donnell et al. 2005; Xiao et al. 2008). We first confirmed that *miR-19* directly acts on the *Pten* 3'UTR via binding to the two predicted sites by performing reporter assays in human cancer cells and in *miR-17~92^{+/+}* and *miR-17~92^{Δ/Δ}* mouse embryo fibroblasts (Supplemental Fig. 4). We next determined the extent to which *Pten* expression is modulated by *miR-19* in Myc-driven B-cell lymphomas. Western blotting and immunohistochemistry analysis of *miR-17~92^{fl/fl}* and *miR-17~92^{Δ/Δ}* lymphomas confirmed a consistent up-regulation of *Pten* expression in the latter (Fig. 5B,C). Reintroduction of full-length *miR-17~92* or of *miR-19a* and *miR-19b* alone, but not of *miR-17~92^{Δ19a,b}*, in *miR-17~92^{Δ/Δ}* lymphomas was sufficient to restore *Pten* expression to levels similar to those observed in *miR-17~92^{fl/fl}* cells (Fig. 5B,C). In addition, analogous to reintroduction of *miR-19*, RNAi-mediated knockdown of *Pten* in *miR-17~92^{Δ/Δ}* lymphoma cells was sufficient to reduce spontaneous apoptosis to the levels observed in *miR-17~92^{fl/fl}* cells (Fig. 5D). We next examined whether *Pten* knockdown was also sufficient to restore the tumorigenicity of *miR-17~92^{Δ/Δ}* lymphoma cells. Mice injected with *miR-17~92^{Δ/Δ}*; sh-*Pten* developed aggressive lymphomas that led to death with a latency similar to that observed in mice injected with *miR-17~92^{Δ/Δ}* cells ectopically expressing *miR-19a/b* (Fig. 5D). Also in




Figure 4. An in vitro RNAi screen to identify functionally relevant *miR-19* targets. (A) List of the genes assayed in the in vitro shRNA screen. (B) Scatter plot summarizing the result of the screen. Each dot represents an individual shRNA construct. The X-axis is the percentage of GFP cells at the beginning of the experiment (2 d after infection) and the Y-axis is the percentage of GFP cells 11 d later. The green dot identifies the empty vector control. shRNAs that scored positive in the screen are highlighted in red and labeled. Dots corresponding to genes for which at least two out of three shRNAs provided significant growth advantage are labeled. PIG-*miR-19a/b* was included in the screen as positive control (blue dot).




Figure 5. *Pten* is a functionally relevant *miR-19* target in B-cell lymphomas. (A) Schematic representation of the *Pten* 3'UTR with the location of the predicted binding sites for members of the *miR-17~92* cluster and sequence alignments between *miR-19b* and its two predicted binding sites. (B) Pten Western blot on lysates of B-lymphoma cells transduced with the indicated PIG constructs. (Lanes 8,9) For comparison, lysates from *miR-17~92 Δ/Δ* cell expressing the two *Pten* shRNAs that scored positive in the *in vitro* screen were also assayed. (C) Pten immunohistochemistry on lymphoma sections obtained from mice injected with *miR-17~92 Δ/Δ* B-lymphoma cells transduced with the indicated *miR-17~92* derivatives (objective, 20 \times). Brown staining indicates Pten signal. (D) Knockdown of *Pten* suppresses apoptosis in *miR-17~92 Δ/Δ* cells. Apoptosis was measured by detecting caspase activity in *miR-17~92 Δ/Δ* and *miR-17~92 Δ/Δ* cells transduced with the indicated retroviruses. (E) Kaplan-Meier survival curve of mice injected with *miR-17~92 Δ/Δ* lymphoma cells transduced with retroviruses expressing shRNAs against *Pten*. $N = 10$ (five mice for shPten-1 and five mice for shPten-2). For comparison, the survival curves of mice injected with *miR-17~92 Δ/Δ* , *miR-17~92 Δ/Δ* + *miR-19a,b* from Figure 2C are included.

this case, survival was slightly longer compared with mice injected with *miR-17~92 Δ/Δ* cells ($P = 0.0002$), indicating the existence of additional functionally relevant targets.

In summary, the results presented here provide a mechanistic explanation for the functional cooperation between *c-Myc* and *miR-17~92*, identify the *miR-19* seed family as the primary oncogenic determinant of this cluster, and pave the way for the development of novel anti-cancer strategies based on the pharmacological inhibition of *miR-19* function.

Material and methods

Mouse husbandry

Animal studies and procedures were approved by the Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use Committee. Mice were maintained in a mixed 129SvJae and C57/B6 background. The *Rosa26-Cre-ER $T2$* and *miR-17~92 Δ/Δ* mice have been described previously (Ventura et al. 2007, 2008). The *E μ -Myc* mice were generated and described by Adams et al. (1985).

For the *in vivo* tumorigenicity studies, 4- to 8-wk-old athymic (nu/nu) mice were injected intravenously with 10^5 lymphoma cells and monitored daily. Mice were euthanized when moribund. Kaplan-Meier curves were plotted using PRISM software, and the log-rank Mantel-Cox test was used to determine statistical significance.

Antibodies and immunohistochemistry

Antibodies and experimental conditions for Western blotting and immunohistochemistry are described in the Supplemental Material.

Cell culture and retroviral transduction

The *E μ -Myc;miR-17~92 Δ/Δ ;Cre-ER $T2$* lymphoma lines were cultured on a feeder of irradiated NIH-3T3 cells in a medium composed of 50% DMEM and 50% IMDM, supplemented with 10% fetal bovine serum.

To induce deletion of the *miR-17~92* cluster, cells were incubated for 4 d with 250 nM 4-OHT. During our initial set of experiments with

4-OHT-treated lymphoma cells, we noticed that, upon prolonged passages, the few cells that had escaped full *miR-17~92* deletion (*miR-17~92 Δ/Δ* and *miR-17~92 Δ/Δ*) invariably outcompeted the *miR-17~92 Δ/Δ* cells, eventually becoming the majority within a couple of weeks. To avoid this limitation and allow the execution of long-term *in vivo* experiments, 4 d after 4-OHT treatment, subclones were isolated by plating 10 cells per well into a 96-well plate using a MoFlo fluorescence-activated cell sorter. After expansion, clones composed solely of fully recombined cells were isolated and used for further manipulation.

Retroviruses were generated in Phoenix packaging cells. When required, transduced cells were selected by adding puromycin (2 μ g/mL) to the culture medium for 4 d.

Plasmids and shRNA library

A 1.2-kb fragment encompassing the entire *miR-17~92* cluster was PCR-amplified from mouse genomic DNA and cloned into the MSCV-PIG retroviral vector (a gift from Mike Hemann, Massachusetts Institute of Technology). Deletion mutants were by site-directed PCR and verified by sequencing. Primers and sequences are available on request.

The shRNA library was cloned in the MLP retroviral vector (a gift from Michael Hemann, Massachusetts Institute of Technology). For each gene, three shRNA directed against the coding sequence were designed using the RNAi Central resource created by the laboratory of Greg Hannon (<http://katahdin.cshl.org:9331/siRNA/RNAi.cgi?type=shRNA>). Each construct was sequence-verified.

Apoptosis assays

Apoptosis was measured using the Caspase Detection Kit (Red-VAD-FMK or FITC-VAD-FMK, Calbiochem) and confirmed using the TUNEL assay (In Situ Cell Death Detection Kit, TMR red, Roche) following the manufacturer's instructions.

Gene expression analysis

Total RNA extracted from three technical replicates was hybridized to the Affymetrix 430 A2.0 gene chip, following the manufacturer's instruction. Gene expression was normalized using the GCRMA Bioconductor package, and log expression values were computed using the limma package. For genes with multiple probes, the probe with lowest adjusted P -value

was selected. Genes with a log expression change of <-0.2 in all three comparisons and with an adjusted P -value < 0.05 in at least one comparison were considered for subsequent overlap analysis.

miRNA target predictions

miRNA targets were predicted using miRanda (<http://www.microrna.org>) and TargetScan (<http://www.targetscan.org>). For the cumulative distribution function (CDF) plots, target sites were restricted to perfect seed complementarity between positions 2 and 7 of the miRNA. Empirical cumulative distributions were computed using R `ecdf` function for the set of predicted gene of the transduced miRNAs and for the genes with no target sites (background). P -values were computed using the KS two-sample test.

Acknowledgments

We thank Jane Qiu for technical assistance. A.V. is grateful to Tyler Jacks and Robert Benezra for their generosity and support. This work was funded by the Sidney Kimmel Cancer Research Foundation and the Geoffrey Beene Cancer Research Foundation.

References

- Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. *Nature* **318**: 533–538.
- Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. *Nature* **455**: 64–71.
- Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. 2005. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. *Cell* **122**: 553–563.
- Bartel DP. 2009. MicroRNAs: Target recognition and regulatory functions. *Cell* **136**: 215–233.
- Betel D, Wilson M, Gabow A, Marks DS, Sander C. 2008. The microRNA.org resource: Targets and expression. *Nucleic Acids Res* **36**: D149–D153. doi: 10.1093/nar/gkm995.
- Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998. Pten is essential for embryonic development and tumour suppression. *Nat Genet* **19**: 348–355.
- Fontana L, Fiori ME, Albini S, Cifaldi L, Giovannazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, et al. 2008. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. *PLoS One* **3**: e2236. doi: 1371/journal.pone.0002236.
- Grimson A, Farh KK, Johnston WK, Garrett-Engel P, Lim LP, Bartel DP. 2007. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. *Mol Cell* **27**: 91–105.
- Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. 2005. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. *Cancer Res* **65**: 9628–9632.
- He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al. 2005. A microRNA polycistron as a potential human oncogene. *Nature* **435**: 828–833.
- John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. 2004. Human microRNA targets. *PLoS Biol* **2**: e363. doi: 10.1371/journal.pbio.0020363.
- Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al. 2005. Combinatorial microRNA target predictions. *Nat Genet* **37**: 495–500.
- Lim LP, Lau N, Garrett-Engel P, Grimson A, Schelter J, Castle J, Bartel DP, Linsley PS, Johnson J. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* **433**: 769–773.
- Mendell JT. 2008. miRNA roles for the miR-17-92 cluster in development and disease. *Cell* **133**: 217–222.
- O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. 2005. c-Myc-regulated microRNAs modulate E2F1 expression. *Nature* **435**: 839–843.
- Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M. 2004. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. *Cancer Res* **64**: 3087–3095.
- Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretto G, Fisher PE, Parsons R. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. *Proc Natl Acad Sci* **96**: 1563–1568.
- Salmena L, Carracedo A, Pandolfi PP. 2008. Tenets of PTEN tumor suppression. *Cell* **133**: 403–414.
- Schmidt-Suppran M, Rajewsky K. 2007. Vagaries of conditional gene targeting. *Nat Immunol* **8**: 665–668.
- Selbach M, Schwanhauser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. Widespread changes in protein synthesis induced by microRNAs. *Nature* **455**: 58–63.
- Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, et al. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. *Curr Biol* **8**: 1169–1178.
- Tagawa H, Seto M. 2005. A microRNA cluster as a target of genomic amplification in malignant lymphoma. *Leukemia* **19**: 2013–2016.
- Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, He L, Ellison D, Gilbertson RJ, Hannon G, et al. 2009. The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. *Proc Natl Acad Sci* **106**: 2812–2817.
- Ventura A, Jacks T. 2009. MicroRNAs and cancer: Short RNAs go a long way. *Cell* **136**: 586–591.
- Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to tumour regression in vivo. *Nature* **445**: 661–665.
- Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, et al. 2008. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell* **132**: 875–886.
- Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. *Nat Immunol* **9**: 405–414.